Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of Apatinib combined with S-1 as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Gastric Cancer
DRUG: Apatinib|DRUG: S-1
Progression Free Survival, Event driven, an expected average of 8 months|Safety will be assessed by incidence of adverse events, An expected average of 8 months
Objective response rate (ORR), An expected average of 8 months|Disease control rate (DCR), An expected average of 8 months|Overall survival (OS), Event driven, an expected average of 24 months|Quality of life (QoL), Quality of life of patient will be measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 \[EORTC QLQ-C30\]., An expected average of 24 months
The purpose of this study is to evaluate the efficacy and safety of Apatinib combined with S-1 as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.